 | • レポートコード：GIR-23F3910 • 出版社/出版日：GlobalInfoResearch / 2023年2月 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Recombinant Antihemophilic Factor Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界の組換え抗血友病因子の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 組換え抗血友病因子市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・200IU、250IU アプリケーション別セグメントは次のように区分されます。 ・病院、薬局 世界の組換え抗血友病因子市場の主要なマーケットプレーヤーは以下のとおりです。 ・Takeda、Bayer、CSL、Pfizer、Biogen、Octapharma、NovoNordisk 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - 組換え抗血友病因子の概要 - タイプ別分析（2017年vs2021年vs2028年）：200IU、250IU - アプリケーション別分析（2017年vs2021年vs2028年）：病院、薬局 - 世界の組換え抗血友病因子市場規模・予測 - 世界の組換え抗血友病因子生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Takeda、Bayer、CSL、Pfizer、Biogen、Octapharma、NovoNordisk ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：200IU、250IU ・アプリケーション別分析2017年-2028年：病院、薬局 ・組換え抗血友病因子の北米市場分析 - 組換え抗血友病因子の北米市場：タイプ別市場規模2017年-2028年 - 組換え抗血友病因子の北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・組換え抗血友病因子のヨーロッパ市場分析 - ：組換え抗血友病因子のヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：組換え抗血友病因子のヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・組換え抗血友病因子のアジア太平洋市場分析 - 組換え抗血友病因子のアジア太平洋市場：タイプ別市場規模2017年-2028年 - 組換え抗血友病因子のアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・組換え抗血友病因子の南米市場分析 - 組換え抗血友病因子の南米市場：タイプ別市場規模2017年-2028年 - 組換え抗血友病因子の南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・組換え抗血友病因子の中東・アフリカ市場分析 - 組換え抗血友病因子の中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 組換え抗血友病因子の中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Recombinant Antihemophilic Factor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Recombinant Antihemophilic Factor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Recombinant Antihemophilic Factor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 200IU segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Recombinant Antihemophilic Factor include Takeda, Bayer, CSL, Pfizer, and Biogen, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Recombinant Antihemophilic Factor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
200IU
250IU
Market segment by Application can be divided into
Hospital
Pharmacy
The key market players for global Recombinant Antihemophilic Factor market are listed below:
Takeda
Bayer
CSL
Pfizer
Biogen
Octapharma
NovoNordisk
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Antihemophilic Factor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Recombinant Antihemophilic Factor, with price, sales, revenue and global market share of Recombinant Antihemophilic Factor from 2019 to 2022.
Chapter 3, the Recombinant Antihemophilic Factor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Antihemophilic Factor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Recombinant Antihemophilic Factor market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Antihemophilic Factor.
Chapter 13, 14, and 15, to describe Recombinant Antihemophilic Factor sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Recombinant Antihemophilic Factor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Recombinant Antihemophilic Factor Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 200IU
1.2.3 250IU
1.3 Market Analysis by Application
1.3.1 Overview: Global Recombinant Antihemophilic Factor Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Recombinant Antihemophilic Factor Market Size & Forecast
1.4.1 Global Recombinant Antihemophilic Factor Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Recombinant Antihemophilic Factor Sales in Volume (2017-2028)
1.4.3 Global Recombinant Antihemophilic Factor Price (2017-2028)
1.5 Global Recombinant Antihemophilic Factor Production Capacity Analysis
1.5.1 Global Recombinant Antihemophilic Factor Total Production Capacity (2017-2028)
1.5.2 Global Recombinant Antihemophilic Factor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Recombinant Antihemophilic Factor Market Drivers
1.6.2 Recombinant Antihemophilic Factor Market Restraints
1.6.3 Recombinant Antihemophilic Factor Trends Analysis
2 Manufacturers Profiles
2.1 Takeda
2.1.1 Takeda Details
2.1.2 Takeda Major Business
2.1.3 Takeda Recombinant Antihemophilic Factor Product and Services
2.1.4 Takeda Recombinant Antihemophilic Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Bayer
2.2.1 Bayer Details
2.2.2 Bayer Major Business
2.2.3 Bayer Recombinant Antihemophilic Factor Product and Services
2.2.4 Bayer Recombinant Antihemophilic Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 CSL
2.3.1 CSL Details
2.3.2 CSL Major Business
2.3.3 CSL Recombinant Antihemophilic Factor Product and Services
2.3.4 CSL Recombinant Antihemophilic Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Recombinant Antihemophilic Factor Product and Services
2.4.4 Pfizer Recombinant Antihemophilic Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Biogen
2.5.1 Biogen Details
2.5.2 Biogen Major Business
2.5.3 Biogen Recombinant Antihemophilic Factor Product and Services
2.5.4 Biogen Recombinant Antihemophilic Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Octapharma
2.6.1 Octapharma Details
2.6.2 Octapharma Major Business
2.6.3 Octapharma Recombinant Antihemophilic Factor Product and Services
2.6.4 Octapharma Recombinant Antihemophilic Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 NovoNordisk
2.7.1 NovoNordisk Details
2.7.2 NovoNordisk Major Business
2.7.3 NovoNordisk Recombinant Antihemophilic Factor Product and Services
2.7.4 NovoNordisk Recombinant Antihemophilic Factor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Recombinant Antihemophilic Factor Breakdown Data by Manufacturer
3.1 Global Recombinant Antihemophilic Factor Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Recombinant Antihemophilic Factor Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Recombinant Antihemophilic Factor
3.4 Market Concentration Rate
3.4.1 Top 3 Recombinant Antihemophilic Factor Manufacturer Market Share in 2021
3.4.2 Top 6 Recombinant Antihemophilic Factor Manufacturer Market Share in 2021
3.5 Global Recombinant Antihemophilic Factor Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Recombinant Antihemophilic Factor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Recombinant Antihemophilic Factor Market Size by Region
4.1.1 Global Recombinant Antihemophilic Factor Sales in Volume by Region (2017-2028)
4.1.2 Global Recombinant Antihemophilic Factor Revenue by Region (2017-2028)
4.2 North America Recombinant Antihemophilic Factor Revenue (2017-2028)
4.3 Europe Recombinant Antihemophilic Factor Revenue (2017-2028)
4.4 Asia-Pacific Recombinant Antihemophilic Factor Revenue (2017-2028)
4.5 South America Recombinant Antihemophilic Factor Revenue (2017-2028)
4.6 Middle East and Africa Recombinant Antihemophilic Factor Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Recombinant Antihemophilic Factor Sales in Volume by Type (2017-2028)
5.2 Global Recombinant Antihemophilic Factor Revenue by Type (2017-2028)
5.3 Global Recombinant Antihemophilic Factor Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Recombinant Antihemophilic Factor Sales in Volume by Application (2017-2028)
6.2 Global Recombinant Antihemophilic Factor Revenue by Application (2017-2028)
6.3 Global Recombinant Antihemophilic Factor Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Recombinant Antihemophilic Factor Sales by Type (2017-2028)
7.2 North America Recombinant Antihemophilic Factor Sales by Application (2017-2028)
7.3 North America Recombinant Antihemophilic Factor Market Size by Country
7.3.1 North America Recombinant Antihemophilic Factor Sales in Volume by Country (2017-2028)
7.3.2 North America Recombinant Antihemophilic Factor Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Recombinant Antihemophilic Factor Sales by Type (2017-2028)
8.2 Europe Recombinant Antihemophilic Factor Sales by Application (2017-2028)
8.3 Europe Recombinant Antihemophilic Factor Market Size by Country
8.3.1 Europe Recombinant Antihemophilic Factor Sales in Volume by Country (2017-2028)
8.3.2 Europe Recombinant Antihemophilic Factor Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Recombinant Antihemophilic Factor Sales by Type (2017-2028)
9.2 Asia-Pacific Recombinant Antihemophilic Factor Sales by Application (2017-2028)
9.3 Asia-Pacific Recombinant Antihemophilic Factor Market Size by Region
9.3.1 Asia-Pacific Recombinant Antihemophilic Factor Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Recombinant Antihemophilic Factor Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Recombinant Antihemophilic Factor Sales by Type (2017-2028)
10.2 South America Recombinant Antihemophilic Factor Sales by Application (2017-2028)
10.3 South America Recombinant Antihemophilic Factor Market Size by Country
10.3.1 South America Recombinant Antihemophilic Factor Sales in Volume by Country (2017-2028)
10.3.2 South America Recombinant Antihemophilic Factor Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Recombinant Antihemophilic Factor Sales by Type (2017-2028)
11.2 Middle East & Africa Recombinant Antihemophilic Factor Sales by Application (2017-2028)
11.3 Middle East & Africa Recombinant Antihemophilic Factor Market Size by Country
11.3.1 Middle East & Africa Recombinant Antihemophilic Factor Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Recombinant Antihemophilic Factor Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Recombinant Antihemophilic Factor and Key Manufacturers
12.2 Manufacturing Costs Percentage of Recombinant Antihemophilic Factor
12.3 Recombinant Antihemophilic Factor Production Process
12.4 Recombinant Antihemophilic Factor Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Recombinant Antihemophilic Factor Typical Distributors
13.3 Recombinant Antihemophilic Factor Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Recombinant Antihemophilic Factor Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Recombinant Antihemophilic Factor Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Takeda Basic Information, Manufacturing Base and Competitors
Table 4. Takeda Major Business
Table 5. Takeda Recombinant Antihemophilic Factor Product and Services
Table 6. Takeda Recombinant Antihemophilic Factor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Bayer Basic Information, Manufacturing Base and Competitors
Table 8. Bayer Major Business
Table 9. Bayer Recombinant Antihemophilic Factor Product and Services
Table 10. Bayer Recombinant Antihemophilic Factor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. CSL Basic Information, Manufacturing Base and Competitors
Table 12. CSL Major Business
Table 13. CSL Recombinant Antihemophilic Factor Product and Services
Table 14. CSL Recombinant Antihemophilic Factor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Pfizer Basic Information, Manufacturing Base and Competitors
Table 16. Pfizer Major Business
Table 17. Pfizer Recombinant Antihemophilic Factor Product and Services
Table 18. Pfizer Recombinant Antihemophilic Factor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Biogen Basic Information, Manufacturing Base and Competitors
Table 20. Biogen Major Business
Table 21. Biogen Recombinant Antihemophilic Factor Product and Services
Table 22. Biogen Recombinant Antihemophilic Factor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Octapharma Basic Information, Manufacturing Base and Competitors
Table 24. Octapharma Major Business
Table 25. Octapharma Recombinant Antihemophilic Factor Product and Services
Table 26. Octapharma Recombinant Antihemophilic Factor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. NovoNordisk Basic Information, Manufacturing Base and Competitors
Table 28. NovoNordisk Major Business
Table 29. NovoNordisk Recombinant Antihemophilic Factor Product and Services
Table 30. NovoNordisk Recombinant Antihemophilic Factor Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Global Recombinant Antihemophilic Factor Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 32. Global Recombinant Antihemophilic Factor Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 33. Market Position of Manufacturers in Recombinant Antihemophilic Factor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 34. Global Recombinant Antihemophilic Factor Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Recombinant Antihemophilic Factor Production Site of Key Manufacturer
Table 36. Recombinant Antihemophilic Factor New Entrant and Capacity Expansion Plans
Table 37. Recombinant Antihemophilic Factor Mergers & Acquisitions in the Past Five Years
Table 38. Global Recombinant Antihemophilic Factor Sales by Region (2017-2022) & (K Units)
Table 39. Global Recombinant Antihemophilic Factor Sales by Region (2023-2028) & (K Units)
Table 40. Global Recombinant Antihemophilic Factor Revenue by Region (2017-2022) & (USD Million)
Table 41. Global Recombinant Antihemophilic Factor Revenue by Region (2023-2028) & (USD Million)
Table 42. Global Recombinant Antihemophilic Factor Sales by Type (2017-2022) & (K Units)
Table 43. Global Recombinant Antihemophilic Factor Sales by Type (2023-2028) & (K Units)
Table 44. Global Recombinant Antihemophilic Factor Revenue by Type (2017-2022) & (USD Million)
Table 45. Global Recombinant Antihemophilic Factor Revenue by Type (2023-2028) & (USD Million)
Table 46. Global Recombinant Antihemophilic Factor Price by Type (2017-2022) & (USD/Unit)
Table 47. Global Recombinant Antihemophilic Factor Price by Type (2023-2028) & (USD/Unit)
Table 48. Global Recombinant Antihemophilic Factor Sales by Application (2017-2022) & (K Units)
Table 49. Global Recombinant Antihemophilic Factor Sales by Application (2023-2028) & (K Units)
Table 50. Global Recombinant Antihemophilic Factor Revenue by Application (2017-2022) & (USD Million)
Table 51. Global Recombinant Antihemophilic Factor Revenue by Application (2023-2028) & (USD Million)
Table 52. Global Recombinant Antihemophilic Factor Price by Application (2017-2022) & (USD/Unit)
Table 53. Global Recombinant Antihemophilic Factor Price by Application (2023-2028) & (USD/Unit)
Table 54. North America Recombinant Antihemophilic Factor Sales by Country (2017-2022) & (K Units)
Table 55. North America Recombinant Antihemophilic Factor Sales by Country (2023-2028) & (K Units)
Table 56. North America Recombinant Antihemophilic Factor Revenue by Country (2017-2022) & (USD Million)
Table 57. North America Recombinant Antihemophilic Factor Revenue by Country (2023-2028) & (USD Million)
Table 58. North America Recombinant Antihemophilic Factor Sales by Type (2017-2022) & (K Units)
Table 59. North America Recombinant Antihemophilic Factor Sales by Type (2023-2028) & (K Units)
Table 60. North America Recombinant Antihemophilic Factor Sales by Application (2017-2022) & (K Units)
Table 61. North America Recombinant Antihemophilic Factor Sales by Application (2023-2028) & (K Units)
Table 62. Europe Recombinant Antihemophilic Factor Sales by Country (2017-2022) & (K Units)
Table 63. Europe Recombinant Antihemophilic Factor Sales by Country (2023-2028) & (K Units)
Table 64. Europe Recombinant Antihemophilic Factor Revenue by Country (2017-2022) & (USD Million)
Table 65. Europe Recombinant Antihemophilic Factor Revenue by Country (2023-2028) & (USD Million)
Table 66. Europe Recombinant Antihemophilic Factor Sales by Type (2017-2022) & (K Units)
Table 67. Europe Recombinant Antihemophilic Factor Sales by Type (2023-2028) & (K Units)
Table 68. Europe Recombinant Antihemophilic Factor Sales by Application (2017-2022) & (K Units)
Table 69. Europe Recombinant Antihemophilic Factor Sales by Application (2023-2028) & (K Units)
Table 70. Asia-Pacific Recombinant Antihemophilic Factor Sales by Region (2017-2022) & (K Units)
Table 71. Asia-Pacific Recombinant Antihemophilic Factor Sales by Region (2023-2028) & (K Units)
Table 72. Asia-Pacific Recombinant Antihemophilic Factor Revenue by Region (2017-2022) & (USD Million)
Table 73. Asia-Pacific Recombinant Antihemophilic Factor Revenue by Region (2023-2028) & (USD Million)
Table 74. Asia-Pacific Recombinant Antihemophilic Factor Sales by Type (2017-2022) & (K Units)
Table 75. Asia-Pacific Recombinant Antihemophilic Factor Sales by Type (2023-2028) & (K Units)
Table 76. Asia-Pacific Recombinant Antihemophilic Factor Sales by Application (2017-2022) & (K Units)
Table 77. Asia-Pacific Recombinant Antihemophilic Factor Sales by Application (2023-2028) & (K Units)
Table 78. South America Recombinant Antihemophilic Factor Sales by Country (2017-2022) & (K Units)
Table 79. South America Recombinant Antihemophilic Factor Sales by Country (2023-2028) & (K Units)
Table 80. South America Recombinant Antihemophilic Factor Revenue by Country (2017-2022) & (USD Million)
Table 81. South America Recombinant Antihemophilic Factor Revenue by Country (2023-2028) & (USD Million)
Table 82. South America Recombinant Antihemophilic Factor Sales by Type (2017-2022) & (K Units)
Table 83. South America Recombinant Antihemophilic Factor Sales by Type (2023-2028) & (K Units)
Table 84. South America Recombinant Antihemophilic Factor Sales by Application (2017-2022) & (K Units)
Table 85. South America Recombinant Antihemophilic Factor Sales by Application (2023-2028) & (K Units)
Table 86. Middle East & Africa Recombinant Antihemophilic Factor Sales by Region (2017-2022) & (K Units)
Table 87. Middle East & Africa Recombinant Antihemophilic Factor Sales by Region (2023-2028) & (K Units)
Table 88. Middle East & Africa Recombinant Antihemophilic Factor Revenue by Region (2017-2022) & (USD Million)
Table 89. Middle East & Africa Recombinant Antihemophilic Factor Revenue by Region (2023-2028) & (USD Million)
Table 90. Middle East & Africa Recombinant Antihemophilic Factor Sales by Type (2017-2022) & (K Units)
Table 91. Middle East & Africa Recombinant Antihemophilic Factor Sales by Type (2023-2028) & (K Units)
Table 92. Middle East & Africa Recombinant Antihemophilic Factor Sales by Application (2017-2022) & (K Units)
Table 93. Middle East & Africa Recombinant Antihemophilic Factor Sales by Application (2023-2028) & (K Units)
Table 94. Recombinant Antihemophilic Factor Raw Material
Table 95. Key Manufacturers of Recombinant Antihemophilic Factor Raw Materials
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Recombinant Antihemophilic Factor Typical Distributors
Table 99. Recombinant Antihemophilic Factor Typical Customers
List of Figures
Figure 1. Recombinant Antihemophilic Factor Picture
Figure 2. Global Recombinant Antihemophilic Factor Revenue Market Share by Type in 2021
Figure 3. 200IU
Figure 4. 250IU
Figure 5. Global Recombinant Antihemophilic Factor Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Pharmacy
Figure 8. Global Recombinant Antihemophilic Factor Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Recombinant Antihemophilic Factor Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Recombinant Antihemophilic Factor Sales (2017-2028) & (K Units)
Figure 11. Global Recombinant Antihemophilic Factor Price (2017-2028) & (USD/Unit)
Figure 12. Global Recombinant Antihemophilic Factor Production Capacity (2017-2028) & (K Units)
Figure 13. Global Recombinant Antihemophilic Factor Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Recombinant Antihemophilic Factor Market Drivers
Figure 15. Recombinant Antihemophilic Factor Market Restraints
Figure 16. Recombinant Antihemophilic Factor Market Trends
Figure 17. Global Recombinant Antihemophilic Factor Sales Market Share by Manufacturer in 2021
Figure 18. Global Recombinant Antihemophilic Factor Revenue Market Share by Manufacturer in 2021
Figure 19. Recombinant Antihemophilic Factor Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Recombinant Antihemophilic Factor Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Recombinant Antihemophilic Factor Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Recombinant Antihemophilic Factor Sales Market Share by Region (2017-2028)
Figure 23. Global Recombinant Antihemophilic Factor Revenue Market Share by Region (2017-2028)
Figure 24. North America Recombinant Antihemophilic Factor Revenue (2017-2028) & (USD Million)
Figure 25. Europe Recombinant Antihemophilic Factor Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Recombinant Antihemophilic Factor Revenue (2017-2028) & (USD Million)
Figure 27. South America Recombinant Antihemophilic Factor Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Recombinant Antihemophilic Factor Revenue (2017-2028) & (USD Million)
Figure 29. Global Recombinant Antihemophilic Factor Sales Market Share by Type (2017-2028)
Figure 30. Global Recombinant Antihemophilic Factor Revenue Market Share by Type (2017-2028)
Figure 31. Global Recombinant Antihemophilic Factor Price by Type (2017-2028) & (USD/Unit)
Figure 32. Global Recombinant Antihemophilic Factor Sales Market Share by Application (2017-2028)
Figure 33. Global Recombinant Antihemophilic Factor Revenue Market Share by Application (2017-2028)
Figure 34. Global Recombinant Antihemophilic Factor Price by Application (2017-2028) & (USD/Unit)
Figure 35. North America Recombinant Antihemophilic Factor Sales Market Share by Type (2017-2028)
Figure 36. North America Recombinant Antihemophilic Factor Sales Market Share by Application (2017-2028)
Figure 37. North America Recombinant Antihemophilic Factor Sales Market Share by Country (2017-2028)
Figure 38. North America Recombinant Antihemophilic Factor Revenue Market Share by Country (2017-2028)
Figure 39. United States Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Recombinant Antihemophilic Factor Sales Market Share by Type (2017-2028)
Figure 43. Europe Recombinant Antihemophilic Factor Sales Market Share by Application (2017-2028)
Figure 44. Europe Recombinant Antihemophilic Factor Sales Market Share by Country (2017-2028)
Figure 45. Europe Recombinant Antihemophilic Factor Revenue Market Share by Country (2017-2028)
Figure 46. Germany Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Recombinant Antihemophilic Factor Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Recombinant Antihemophilic Factor Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Recombinant Antihemophilic Factor Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Recombinant Antihemophilic Factor Revenue Market Share by Region (2017-2028)
Figure 55. China Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Recombinant Antihemophilic Factor Sales Market Share by Type (2017-2028)
Figure 62. South America Recombinant Antihemophilic Factor Sales Market Share by Application (2017-2028)
Figure 63. South America Recombinant Antihemophilic Factor Sales Market Share by Country (2017-2028)
Figure 64. South America Recombinant Antihemophilic Factor Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Recombinant Antihemophilic Factor Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Recombinant Antihemophilic Factor Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Recombinant Antihemophilic Factor Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Recombinant Antihemophilic Factor Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Recombinant Antihemophilic Factor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Recombinant Antihemophilic Factor in 2021
Figure 76. Manufacturing Process Analysis of Recombinant Antihemophilic Factor
Figure 77. Recombinant Antihemophilic Factor Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source